Matinas BioPharma News

Matinas BioPharma's LNC Platform For The Delivery Of Small Oligonucleotides Featured In Two Presentations At The ASGCT Annual Meeting

Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology,

BenzingaMay 7 20:04

Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal

GlobeNewswireMay 2 19:00

In Vivo Efficacy of Matinas BioPharma's Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden and improvement in lung infectionBEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas Bi

GlobeNewswireApr 30 20:00

Matinas BioPharma's Multi-Million Share Sale and Lock-Up Deal

TipRanksApr 5 19:12

Matinas BioPharma Prices $10 Million Registered Direct Offering

BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) ("Matinas BioPharma" or the "Company"), a clinical-stage biopharmaceutical company focused on delivering groundbreaking

GlobeNewswireApr 3 20:30

Matinas BioPharma (MTNB) Gets a Buy From Maxim Group

TipRanksApr 2 22:35

12 Health Care Stocks Moving In Monday's After-Market Session

GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in

BenzingaApr 2 04:31

Earnings Call Summary | Matinas BioPharma(MTNB.US) Q4 2023 Earnings Conference

The following is a summary of the Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript:Financial Performance:Matinas BioPharma reported a revenue of $1.1 million for 2023, primaril

Futu NewsMar 29 12:05 · Conference Call

Matinas BioPharma Updates Presentation for Investor Outreach

TipRanksMar 28 21:13

Matinas BioPharma Hldgs Q4 EPS $(0.03) Down From $(0.02) YoY

Matinas BioPharma Hldgs (AMEX:MTNB) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year.

BenzingaMar 28 11:42

Matinas Biopharma GAAP EPS of -$0.11, Revenue of $1.1M

Seeking AlphaMar 28 04:46

Matinas BioPharma FY23 EPS $(0.11) Vs $(0.10) YoY

2023 Financial ResultsRevenue for 2023 was $1.1 million, which was generated from the Company's research collaborations with BioNTech SE and Genentech Inc. This compares with revenue for 2022 of $3.2

BenzingaMar 28 04:34

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) reports 2023 financial results and provides a business update.

Matinas BioPharmaMar 28 04:05

Matinas BioPharma's LNC Technology Promises Safer Chemotherapy

TipRanksMar 25 20:22

Matinas BioPharma Announces Positive in Vivo Safety Data With Its Oral LNC-Docetaxel Formulation

Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data

GlobeNewswireMar 25 20:00

Matinas BioPharma's MAT2203 Shows Promising Clinical Results

TipRanksMar 22 21:33

Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203

Matinas BioPharma Announces Complete Clinical Response In Three Patients With Serious Invasive Fusarium Infection Following Treatment With MAT2203

BenzingaMar 22 21:16

Three Patients With Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces complete clinical response in three patients with serious invasive fusarium infection following treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B.

GlobeNewswireMar 22 21:15

Matinas BioPharma Regains Compliance With NYSE American Continued Listing Standards

BEDMINSTER, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal

GlobeNewswireMar 22 18:30

Matinas BioPharma's MAT2203 Shows Renal Improvement and Infection Recovery

TipRanksFeb 26 21:22